You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

MAVIK Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Mavik, and what generic alternatives are available?

Mavik is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in MAVIK is trandolapril. There are ten drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the trandolapril profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Mavik

A generic version of MAVIK was approved as trandolapril by AUROBINDO PHARMA on June 12th, 2007.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for MAVIK?
  • What are the global sales for MAVIK?
  • What is Average Wholesale Price for MAVIK?
Summary for MAVIK
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 75
Patent Applications: 4,506
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in MAVIK?MAVIK excipients list
DailyMed Link:MAVIK at DailyMed
Drug patent expirations by year for MAVIK
Paragraph IV (Patent) Challenges for MAVIK
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
MAVIK Tablets trandolapril 1 mg, 2 mg and 4 mg 020528 1 2004-10-04

US Patents and Regulatory Information for MAVIK

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie MAVIK trandolapril TABLET;ORAL 020528-001 Apr 26, 1996 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie MAVIK trandolapril TABLET;ORAL 020528-002 Apr 26, 1996 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie MAVIK trandolapril TABLET;ORAL 020528-003 Apr 26, 1996 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MAVIK

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie MAVIK trandolapril TABLET;ORAL 020528-002 Apr 26, 1996 ⤷  Sign Up ⤷  Sign Up
Abbvie MAVIK trandolapril TABLET;ORAL 020528-002 Apr 26, 1996 ⤷  Sign Up ⤷  Sign Up
Abbvie MAVIK trandolapril TABLET;ORAL 020528-001 Apr 26, 1996 ⤷  Sign Up ⤷  Sign Up
Abbvie MAVIK trandolapril TABLET;ORAL 020528-003 Apr 26, 1996 ⤷  Sign Up ⤷  Sign Up
Abbvie MAVIK trandolapril TABLET;ORAL 020528-001 Apr 26, 1996 ⤷  Sign Up ⤷  Sign Up
Abbvie MAVIK trandolapril TABLET;ORAL 020528-002 Apr 26, 1996 ⤷  Sign Up ⤷  Sign Up
Abbvie MAVIK trandolapril TABLET;ORAL 020528-001 Apr 26, 1996 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for MAVIK

See the table below for patents covering MAVIK around the world.

Country Patent Number Title Estimated Expiration
Japan S58118569 NOVEL DERIVATIVE OF BICYCLOAMINO ACID ⤷  Sign Up
Austria 25244 ⤷  Sign Up
Finland 80675 ⤷  Sign Up
Austria 98128 ⤷  Sign Up
Norway 156786 ⤷  Sign Up
Japan H01301695 NOVEL DERIVATIVE OF BICYCLIC AMINO ACID ⤷  Sign Up
Portugal 76052 NEUE DERIVATE BICYCLISCHER AMINOSAEUREN VERFAHREN ZU IHRER HERSTELLUNG DIESE ENTHALTENDE MITTEL UND DEREN VERWENDUNG SOWIE NEUE BICYCLISCHE AMINOSAEUREN ALS ZWISCHENSTUFEN UND VERFAHREN ZU DEREN HERSTELLUNG ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for MAVIK

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0084164 SPC/GB93/146 United Kingdom ⤷  Sign Up SPC/GB93/146:, EXPIRES: 20070218
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.